Point72 (DIFC)’s Trevi Therapeutics TRVI Stock Holding History

Point72 (DIFC)’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-461	Closed	-$2.52K	–	1865
2025 Q2	$2.52K	Buy	+461	New	+$2.87K	﹤0.01%	1415

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Point72 (DIFC)'s TRVI Position: Q3 2025 in Review

Point72 (DIFC) sold out of Trevi Therapeutics (TRVI) in Q3 2025, closing a stake of 461 shares — an estimated $2.52K sold.

Point72 (DIFC) first reported a position in TRVI in Q2 2025 and held it in 1 quarter. The position peaked at $2.52K in Q2 2025. 164 funds tracked by Wall St. Rank hold TRVI as of Q3 2025.

Point72 (DIFC) reported no remaining Trevi Therapeutics position as of Q3 2025 after selling out during the quarter.
Point72 (DIFC) sold 461 Trevi Therapeutics shares in Q3 2025, an estimated $2.52K.
Point72 (DIFC) first reported a position in Trevi Therapeutics in Q2 2025 and held it in 1 quarter.
Point72 (DIFC)'s Trevi Therapeutics position peaked at $2.52K in Q2 2025.
164 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.